Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older and have a known or suspected cancer, as well as healthy volunteers in the same age range.
- People whose physical functioning falls within a certain range, rated on a standard medical scale from fully active (0) to limited self-care (3) — this is something the trial site would assess.
- People who are able to understand what the trial involves and are willing to sign a written consent form.
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial.
Note on a historical part of this trial: An earlier phase of the trial involved a blood collection procedure called apheresis. That part of the trial is no longer active, but for reference, it had additional requirements including a minimum blood count, weight over 25 kg, being HIV negative, normal blood clotting results, and having suitable vein access. These requirements are no longer relevant to joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jennifer L Marte, National Cancer Institute (NCI)
Phone: (240) 529-3415
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis.; Correlate analysis results with clinical parameters such as demographics, toxicities, and treatment outcomes.; Collection of tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.